Evoke Pharma Operating Income 2013-2025 | EVOK
Evoke Pharma operating income from 2013 to 2025. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
|
Evoke Pharma Annual Operating Income (Millions of US $) |
|
|---|---|
| 2024 | $-5 |
| 2023 | $-7 |
| 2022 | $-8 |
| 2021 | $-8 |
| 2020 | $-13 |
| 2019 | $-7 |
| 2018 | $-8 |
| 2017 | $-11 |
| 2016 | $-11 |
| 2015 | $-12 |
| 2014 | $-13 |
| 2013 | $-3 |
| 2012 | $-2 |
| 2011 | $-2 |
|
Evoke Pharma Quarterly Operating Income (Millions of US $) |
|
|---|---|
| 2025-09-30 | $-1 |
| 2025-06-30 | $-2 |
| 2025-03-31 | $-1 |
| 2024-12-31 | $-1 |
| 2024-09-30 | $-1 |
| 2024-06-30 | $-1 |
| 2024-03-31 | $-2 |
| 2023-12-31 | $-2 |
| 2023-09-30 | $-2 |
| 2023-06-30 | $-2 |
| 2023-03-31 | $-2 |
| 2022-12-31 | $-2 |
| 2022-09-30 | $-2 |
| 2022-06-30 | $-2 |
| 2022-03-31 | $-2 |
| 2021-12-31 | $-2 |
| 2021-09-30 | $-2 |
| 2021-06-30 | $-2 |
| 2021-03-31 | $-3 |
| 2020-12-31 | $-2 |
| 2020-09-30 | $-2 |
| 2020-06-30 | $-7 |
| 2020-03-31 | $-2 |
| 2019-12-31 | $-1 |
| 2019-09-30 | $-2 |
| 2019-06-30 | $-2 |
| 2019-03-31 | $-2 |
| 2018-12-31 | $-2 |
| 2018-09-30 | $-2 |
| 2018-06-30 | $-2 |
| 2018-03-31 | $-2 |
| 2017-12-31 | $-3 |
| 2017-09-30 | $-4 |
| 2017-06-30 | $-3 |
| 2017-03-31 | $-2 |
| 2016-12-31 | $-2 |
| 2016-09-30 | $-2 |
| 2016-06-30 | $-3 |
| 2016-03-31 | $-3 |
| 2015-12-31 | $-3 |
| 2015-09-30 | $-3 |
| 2015-06-30 | $-3 |
| 2015-03-31 | $-3 |
| 2014-12-31 | $-3 |
| 2014-09-30 | $-4 |
| 2014-06-30 | $-3 |
| 2014-03-31 | $-3 |
| 2013-12-31 | $-2 |
| 2013-09-30 | $0 |
| 2013-06-30 | $0 |
| 2013-03-31 | $0 |
| 2012-09-30 | $0 |
| 2012-06-30 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.019B | $0.010B |
| Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |